Viola Akopian

Vice President, Pharmaceutical Development at Regulus Therapeutics, Inc.

Viola Akopian

Viola Akopian

Vice President, Pharmaceutical Development at Regulus Therapeutics, Inc.

Biography

Viola Akopian, Ph.D.

Dr. Violetta Akopian joined Regulus in January 2014 as Senior Director, Quality and Drug Product Development and was promoted to Vice President, Pharmaceutical Development in September 2016. Prior to Regulus, Dr. Akopian was responsible for CMC and Quality for Nitto Denko Technical Corporation’s (now Nitto Biopharma) Molecular Therapeutics Department. Prior to Nitto Biopharma, Dr. Akopian held multiple senior positions in pharmaceutical companies and government agencies in Canada, leading manufacturing and CMC development programs for oligonucleotide-based therapeutics. Dr. Akopian obtained a M.Sc. in Biochemistry and a Ph.D. in Biology at the Russian Academy of Science in St. Petersburg. She received her post-doctoral training at Erasmus University of Rotterdam and in the Department of Cancer Endocrinology at the BC Cancer Agency.

Overview
RelSci Relationships

32

Relationships
RelSci Relationships are individuals Viola Akopian likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at AmpliPhi Biosciences Corp.

Relationship likelihood: Average

Chief Research & Development Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Leader at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Founder at SENTÉ, Inc. (California)

Relationship likelihood: Average

Chief Financial & Accounting Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Senior Vice President, General Counsel, Business Development & Corporate Secretary at Heron Therapeutics, Inc.

Relationship likelihood: Average

Former Chief Medical Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Director at Regulus Therapeutics, Inc.

Relationship likelihood: Average

President & Chief Executive Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Chief Executive Officer & Director at TCR2 Therapeutics, Inc.

Relationship likelihood: Average

Paths to Viola Akopian
Potential Connections via
Relationship Science
You
Viola Akopian
Vice President, Pharmaceutical Development at Regulus Therapeutics, Inc.
Career History
Vice President, Pharmaceutical Development
Tenure Unconfirmed

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Other Affiliations

Viola Akopian is affiliated with Regulus Therapeutics, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Viola Akopian. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Viola Akopian's profile does not indicate a business or promotional relationship of any kind between RelSci and Viola Akopian.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/viola-akopian-223209180
  • https://relationshipscience.com/person/viola-akopian-223209180